BioSyent Releases Financial Results for Q1 2022
May 18, 2022 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 18, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2022. Key highlights...
BioSyent Schedules Q1 2022 Earnings Release for May 18, 2022
May 10, 2022 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2022 on...
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Seventh Consecutive Year
May 02, 2022 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 02, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the seventh consecutive year, FeraMAX® is the #1 recommended iron...
Pour la septième année consécutive, FeraMAXᴹᴰ est le 1ᴱᴿ choix de marque de supplément de fer recommandée par les pharmaciens et les médecins canadiens
May 02, 2022 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, 02 mai 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », Bourse de croissance TSX : RX) a le plaisir d’annoncer que pour la septième année consécutive, FeraMAXMD est le...
BioSyent to Present at 2022 Bloom Burton & Co. Healthcare Investor Conference
April 26, 2022 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 26, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2022 Bloom Burton & Co....
BioSyent Announces Grant of Restricted Share Units
March 31, 2022 16:55 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 31, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 56,957 Restricted...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2021
March 09, 2022 16:34 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 09, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2021. Key...
BioSyent Schedules Q4 and Full Year 2021 Earnings Release for March 9, 2022
March 03, 2022 16:28 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 03, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent Adopts Advance Notice By-law
February 11, 2022 09:29 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 11, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that its Board of Directors has approved the adoption of an Advance...
BioSyent Announces Renewal of Normal Course Issuer Bid
December 13, 2021 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...